Trump’s FDA Chief Pledges To Open Investigation Into Dangerous Abortion Pills After ACLJ Letter

In a major step forward for the pro-life movement and for the protection of women’s health, leading medical voices and legal advocates are calling out the Biden FDA’s reckless approval and deregulation of the abortion drug mifepristone. The ACLJ has been at the forefront of this battle, sounding the alarm about the dangers of chemical abortion and urging the federal government to reverse course. Now, momentum is building.

Recently, President Trump’s FDA Commissioner, Dr. Marty Makary pledged that the FDA would “conduct a review” of its approval of mifepristone.

This is a critical victory – not just for unborn children but for the women whose health has been tossed aside by a radical abortion agenda. This comes just two weeks after we sent a letter to FDA Commissioner Makary asking for the agency’s intervention on behalf of women and babies.

The ACLJ has long warned about this very danger. In our letter, we detailed how the Biden Administration recklessly expanded access to mifepristone through mail-order abortion and by stripping away critical safety protocols. We are urging federal officials to roll back this politically motivated deregulation and restore medically necessary safeguards.

This isn’t just a policy debate – it’s a matter of life and death. Women are being told this drug is “safe,” while real-world reports show a trail of devastating consequences. The Biden Administration’s aggressive push to normalize and distribute mifepristone without appropriate oversight puts ideology above science and politics above people.

We are witnessing the fruit of advocacy, and it is a clear sign that truth is breaking through the abortion industry’s disinformation campaign. Medical professionals are no longer staying silent. Legal and policy experts are standing firm. The ACLJ is proud to be among those leading the charge – defending life, fighting for women’s health, and calling for the FDA to do its job and regulate this dangerous and deadly drug like any other high-risk medication.

This momentum marks a positive step in the fight for life, but it is only the beginning. The abortion lobby will not relent. That’s why we must continue pressing forward – holding our leaders accountable and demanding that women and unborn children be protected from the deadly consequences of chemical abortion.

We are grateful to the Trump Administration for engaging this critical issue to ensure that women and children alike are protected from dangerous drugs that are being peddled by the abortion industry.

As we previously explained:

In 2022 alone, chemical abortions accounted for 63% of all abortions in the United States, totaling 642,700. Shockingly, this number is believed to be underreported, with many telehealth providers and foreign suppliers skirting U.S. law and safety regulations.

A recent study involving 865,727 women prescribed mifepristone (abortion pills) between 2017 and 2023 revealed the chilling reality:

• 28,658 cases of hemorrhage
• 40,960 emergency room visits
•  3,062 ectopic pregnancies
• 24,563 required surgical abortions
• 49,169 other abortion-specific complications

In fact, 11% of women who took these abortion pills suffered very severe adverse health effects leading to hospitalization, 22% higher than the FDA’s label indicates, and HHS Secretary RFK Jr. called this revelation “alarming.” These numbers expose the lie that is being spoon-fed to women by the abortion lobby and companies making these drugs, such as Mifeprex, which falsely touts only a “0.05% rate” of adverse events. We know now this is simply not true. Maintaining unlimited access is dangerous for everyone.

We will not back down. The ACLJ will continue to work in the courts, in Congress, at the state level, and in the public square to ensure that truth prevails, that lives are saved, and that mifepristone is no longer treated as a tool for political convenience but as the dangerous drug it is.

Join us. Stand for life. Demand accountability.